On Friday, Nautilus Biotechnology Inc (NASDAQ: NAUT) opened higher 9.29% from the last session, before settling in for the closing price of $1.83. Price fluctuations for NAUT have ranged from $0.62 to $2.54 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -4.55%. Company’s average yearly earnings per share was noted 6.25% at the time writing. With a float of $60.06 million, this company’s outstanding shares have now reached $126.31 million.
Nautilus Biotechnology Inc (NAUT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Nautilus Biotechnology Inc is 52.45%, while institutional ownership is 25.79%. The most recent insider transaction that took place on Nov 06 ’25, was worth 5,960. In this transaction Chief Marketing Officer of this company bought 4,000 shares at a rate of $1.49, taking the stock ownership to the 4,000 shares. Before that another transaction happened on Sep 05 ’25, when Company’s CEO, President, and Secretary bought 116,500 for $0.67, making the entire transaction worth $78,544. This insider now owns 10,258,221 shares in total.
Nautilus Biotechnology Inc (NAUT) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.14 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.16) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.67% during the next five years compared to -4.55% drop over the previous five years of trading.
Nautilus Biotechnology Inc (NASDAQ: NAUT) Trading Performance Indicators
Check out the current performance indicators for Nautilus Biotechnology Inc (NAUT). In the past quarter, the stock posted a quick ratio of 14.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.50, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.61 in one year’s time.
